Physician profile
Angel E Llanio
NPI 1174812564
$4,417.19
in general payments reported to CMS, 2019-2025
34 companies · $70.79 in 2025
The $70.79 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $989 · 2020: $131 · 2021: $408 · 2022: $1,242 · 2023: $753 · 2024: $824 · 2025: $70.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,627 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,627.25 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $511.00 | 2019-2024 | Rybelsus, Ozempic |
| Amgen INC. | $475.53 | 2019-2025 | Otezla, Repatha, Krystexxa |
| Abbvie INC. | $441.36 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $416.85 | 2021-2024 | |
| Pfizer INC. | $340.22 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $318.82 | 2019-2024 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $243.58 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Astellas Pharma US INC | $240.63 | 2019-2024 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $223.77 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $166.59 | 2022-2024 | Mounjaro |
| Merck Sharp & Dohme LLC | $98.23 | 2019-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.18 | 2019-2024 | Jardiance |
| Idorsia Pharmaceuticals US INC | $74.26 | 2022-2024 | Quviviq |
| Dexcom, INC. | $70.56 | 2023-2024 | Dexcom G6 Transmitter |
| Antares Pharma, INC. | $69.65 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $63.39 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.36 | 2019-2022 | |
| Watermark Medical, INC. | $56.73 | 2023 | Ares Home Sleep Testing Device |
| Boston Scientific Corporation | $52.51 | 2019-2022 | |
| Heartflow, INC. | $51.51 | 2019 | |
| Allergan, INC. | $46.65 | 2019-2020 | |
| Nevro Corp. | $45.94 | 2022 | |
| Biogen, INC. | $45.62 | 2021 | |
| Janssen Pharmaceuticals, INC | $33.55 | 2019 | |
| Exact Sciences Corporation | $21.47 | 2023 | Cologuard Collection Kit |
| Ge Healthcare | $21.05 | 2020 | |
| Eisai INC. | $20.65 | 2024 | |
| Hologic Sales and Service, LLC | $20.59 | 2021 | |
| Halozyme INC | $20.58 | 2023 | |
| Amarin Pharma, INC. | $19.97 | 2020 | |
| Radius Health, INC. | $17.11 | 2022 | |
| Abbott Laboratories | $16.72 | 2021 | |
| Arbor Pharmaceuticals, INC. | $15.56 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.00 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angel Llanio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.